Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
postMONARCH
2021-002301-10Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Abemaciclib plus fulvestrant with Placebo plus fulvestrant (2 arms). Primary endpoint: Progression-free survival. Started Oct 2021; status: active.
02
Drugs
abemaciclibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2021-002301-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002301-10.